MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Overduin, M.
Right arrow Articles by Kutateladze, T. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Overduin, M.
Right arrow Articles by Kutateladze, T. G.
Molecular Interventions 1:150-159 (2001)
© 2001 American Society of Pharmacology and Experimental Therapeutics


Review

Signaling with Phosphoinositides: Better than Binary

Michael Overduin, Matthew L. Cheever and Tatiana G. Kutateladze

Department of Pharmacology and Molecular Biology Program University of Colorado Health Sciences Center 4200 East Ninth Avenue, Denver, Co 80262

Correspondence: Address correspondence to MO. E-mail Michael.Overduin{at}UCHSC.edu; fax 303-315-7097.


The phosphorylation of proteins has long been regarded as the star mechanism of signal transduction. So, why focus on the phosphorylation of phosphoinositides? Basically, because they're better than binary: The inositol ring of the phosphoinositide head group offers multiple options for modification-and thus multiple options for recognition by the cell signaling network.

When the outside of cell is stimulated,the inside generates a flurry of signals.Phosphates are sprinkled over lipids and proteins,where they are recognized within diverse signaling pathways.The kinases that congregate beneath the cell surface to provide the phosphate tags that mediate signaling have become major targets of new wave of drug design. Phosphoinositide signaling presents a particularly intriguing network whose many mysteries are now being unlocked.Research into protein domains that specifically recognize phosphoinositides have established the ENTH, FYVE,Phox,and pleckstrin homology domains s four cornerstones of phosphoinositide signaling.




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
C.-L. Huang
Complex roles of PIP2 in the regulation of ion channels and transporters
Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1761 - F1765.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Jeganathan and J. M. Lee
Binding of Elongation Factor eEF1A2 to Phosphatidylinositol 4-Kinase beta Stimulates Lipid Kinase Activity and Phosphatidylinositol 4-Phosphate Generation
J. Biol. Chem., January 5, 2007; 282(1): 372 - 380.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Neelon, Y. Wang, B. Stec, and M. F. Roberts
Probing the Mechanism of the Archaeoglobus fulgidus Inositol-1-phosphate Synthase
J. Biol. Chem., March 25, 2005; 280(12): 11475 - 11482.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
J. F. Ellena, J. Moulthrop, J. Wu, M. Rauch, S. Jaysinghne, J. D. Castle, and D. S. Cafiso
Membrane Position of a Basic Aromatic Peptide that Sequesters Phosphatidylinositol 4,5 Bisphosphate Determined by Site-Directed Spin Labeling and High-Resolution NMR
Biophys. J., November 1, 2004; 87(5): 3221 - 3233.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. G. Kutateladze, D. G. S. Capelluto, C. G. Ferguson, M. L. Cheever, A. G. Kutateladze, G. D. Prestwich, and M. Overduin
Multivalent Mechanism of Membrane Insertion by the FYVE Domain
J. Biol. Chem., January 23, 2004; 279(4): 3050 - 3057.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.